Advertisement
Screener

Atlas Venture Life Science Advisors, LLC Historic Quarter Change: USA Stocks, Sold Out

Atlas Venture Life Science Advisors, LLC historic quarter change: USA Stocks, Sold out

In share positions in stocks (listed in the US), over 10 quarters from 2023-12-31 to 2026-06-30, Atlas Venture Life Science Advisors, LLC opened 6 positions, added to 4, reduced 26 and sold out of 8.

  • Q1 2026: Stock DAWN; Country of operation United States; Class Common Stock; Shares before 6,412,560.
  • Q1 2026: Stock GBIO; Country of operation United States; Class Common Stock; Shares before 827,946.
  • Q4 2025: Stock IMA; Country of operation United States; Class Common Stock; Shares before 377,814.
  • Q2 2025: Stock SPRO; Country of operation United States; Class Common Stock; Shares before 305,255.

Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1917529), 10 quarters: Q2 2026 (2026-03-31 to 2026-06-30, filed 2026-08-13); Q1 2026 (2025-12-31 to 2026-03-31, filed 2026-05-14); Q4 2025 (2025-09-30 to 2025-12-31, filed 2026-02-13); Q3 2025 (2025-06-30 to 2025-09-30, filed 2025-11-13); Q2 2025 (2025-03-31 to 2025-06-30, filed 2025-08-12); Q1 2025 (2024-12-31 to 2025-03-31, filed 2025-05-14); Q4 2024 (2024-09-30 to 2024-12-31, filed 2025-02-06); Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-13); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-09); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-06). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2021-12-31.

QuarterStockCountry of operationClassShares beforeShares afterShare changeValue beforeValue afterValue changeFiled
Q1 2026DAWN
Day One Biopharmaceuticals, Inc.
United StatesCommon Stock6,412,5600-6,412,560$59,765,059$0-$59,765,0592026-05-14
Q1 2026GBIO
Generation Bio, Co.
United StatesCommon Stock827,9460-827,946$4,702,732$0-$4,702,7322026-05-14
Q4 2025IMA
ImageneBio, Inc.
United StatesCommon Stock377,8140-377,814$3,079,184$0-$3,079,1842026-02-13
Q2 2025SPRO
Spero Therapeutics, Inc.
United StatesCommon Stock305,2550-305,255$219,784$0-$219,7842025-08-12
Q1 2025TECX
Tectonic Therapeutics, Inc.
United StatesCommon Stock78,4470-78,447$3,621,898$0-$3,621,8982025-05-14
Q4 2024DNTH
Dianthus Therapeutics, Inc.
United StatesCommon Stock76,9790-76,979$2,107,685$0-$2,107,6852025-02-06
Q3 2024REPL
Replimune Group, Inc.
United StatesCommon Stock2,098,3000-2,098,300$18,884,700$0-$18,884,7002024-11-13
Q1 2024AKRO
Akero Therapeutics, Inc.
United StatesCommon Stock359,2510-359,251$8,388,511$0-$8,388,5112024-05-06

Similar Firms

Firm NameCountry13F ValueHoldings
Alpha Wave Global, LPUnited States$0.791B20
Parkway Wealth Management Group, LLCUnited States$0.791B137
Avenir Tech LtdHong Kong$0.790B23
Independence Bank of KentuckyUnited States$0.789B623
Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management)Israel$0.789B85
V3 Holding LtdCayman Islands$0.789B2
Murchinson Ltd.Canada$0.791B95
Aperture Investors, LLCUnited States$0.791B88
Vision Capital Management, Inc.United States$0.792B167
Strategic Wealth Investment Group, LLCUnited States$0.788B94